Table 4.
Detail of methodology for preoperative TACE
| Prior term (17) | Latter term (17) | P | ||
| Selectivity of hepatic artery (%) | Lobe | 2 (12) | 3 (18) | 0.617 |
| Segment | 4 (24) | 5 (29) | ||
| Subsegment or more | 10 (59) | 9 (53) | ||
| Other (1st-branch of right inferior phrenic artery) | 1 (6) | 0 | ||
| Chemotherapeutic agent (%) | Epirubicin | 2 (12) | 3 (18) | 0.153 |
| Epirubicin plus mitomycin C | 5 (29) | 10 (64) | ||
| Cisplatin | 6 (35) | 2 (6) | ||
| Miliplatin | 0 | 1 (6) | ||
| NA | 4 | 1 | ||
| Embolic agent (%) | Gelatin sponge | 12 (71) | 14 (82) | NA |
| NA | 5 | 3 |
NA, not available; TACE, transcatheter arterial chemoembolization.